# OnCo record ropeginterferon-alfa-2b (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ropeginterferon-alfa-2b/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ropeginterferon-alfa-2b" ;
  schema:name "Ropeginterferon alfa-2b"@en ;
  schema:description "Ropeginterferon alfa-2b is a long-acting interferon for polycythaemia vera that, unlike hydroxyurea, can shrink the mutant clone over years."@en ;
  schema:url <https://onco.cc/drugs/ropeginterferon-alfa-2b/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ropeginterferon_alfa-2b> ;
  owl:sameAs <http://www.wikidata.org/entity/Q99754007> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ropeginterferon> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Long-acting mono-pegylated interferon alfa" ;
  schema:alternateName "Besremi" ;
  onco:approval "EU 2019: Polycythaemia vera without symptomatic splenomegaly", "US 2021: Polycythaemia vera" ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/polycythaemia-vera/>, <https://onco.cc/cancers/essential-thrombocythaemia/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:targets <https://onco.cc/targets/jak2/> ;
  onco:companies <https://onco.cc/companies/aop-health/> ;
  onco:trials <https://onco.cc/trials/nct06468033/>, <https://onco.cc/trials/nct05481151/>, <https://onco.cc/trials/nct05485948/>, <https://onco.cc/trials/nct05482971/>, <https://onco.cc/trials/nct04285086/>, <https://onco.cc/trials/nct04655092/> .